Verona Pharma PLC
NASDAQ:VRNA
Verona Pharma PLC
NASDAQ:VRNA
Price:
14.8 USD
-0.54%
Market Closed
Updated:
May 9, 2024
Verona Pharma PLC
Cash from Financing Activities
|
Verona Pharma PLC
Cash from Financing Activities Peer Comparison
Comparables:
GSK
AZN
INDV
HIK
DPH
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Cash from Financing Activities
$92.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Financing Activities
-£6.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Financing Activities
-$2.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
2%
|
|
|
Indivior PLC
LSE:INDV
|
Cash from Financing Activities
-$62m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Financing Activities
-$337m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cash from Financing Activities
£316.5m
|
CAGR 3-Years
39%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
See Also
What is Verona Pharma PLC's Cash from Financing Activities?
Cash from Financing Activities
92.9m
USD
92.9m
USD
Based on the financial report for Dec 31, 2023, Verona Pharma PLC's Cash from Financing Activities amounts to 92.9m USD.
What is Verona Pharma PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-22%
-22%
Over the last year, the Cash from Financing Activities growth was -34%. The average annual Cash from Financing Activities growth rates for Verona Pharma PLC have been -22% over the past three years .
You don't have any saved screeners yet
